X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, Brii will get access to focus on the development of VBI-2601 (BRII-179), a protein-based HBV immunotherapeutic candidate intended for the treatment of chronic HBV infection.
Lead Product(s): BRII-179,Elebsiran
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Brii Biosciences
Deal Size: $33.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition February 13, 2024
Details:
VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.
Lead Product(s): BRII-179,VIR-2218
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Brii Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
Under the collaboration, Brii Bio expanded its exclusive license to VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, to global rights and acquired an exclusive license for PreHevbri, VBI’s 3-antigen hepatitis B vaccine, in the Asia Pacific region (APAC).
Lead Product(s): BRII-179
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Brii Biosciences
Deal Size: $437.0 million Upfront Cash: $15.0 million
Deal Type: Expanded Collaboration July 05, 2023
Details:
VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.
Lead Product(s): BRII-179,VIR-2218
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
The data demonstrate that BRII-835 (VIR-2218), an small interfering ribonucleic acid that mediates RNA interference, results in dose-dependent reduction in hepatitis B surface antigen in Chinese patients with chronic HBV infection who received two doses of BRII-835.
Lead Product(s): VIR-2218,BRII-179
Therapeutic Area: Infections and Infectious Diseases Product Name: VIR-2218
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
The data demonstrate that BRII-179 (VBI-2601) provokes responses in both B cells (antibodies) and T cells of patients with chronic hepatitis B infection (HBV), and was well tolerated, with no signal detection safety.
Lead Product(s): BRII-179
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
BRII-179 (VBI-2601) is a novel recombinant, protein-based immunotherapeutic candidate, which is being developed and led by Brii Bio in partnership with VBI Vaccines (“VBI”) for patients with chronic hepatitis B virus (HBV) infection.
Lead Product(s): BRII-179
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: VBI Vaccines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
